奥希替尼对比化疗在晚期非小细胞肺癌患者报告症状与治疗影响:AURA3试验
AURA3 III期试验中,晚期非小细胞肺癌患者分别接受奥希替尼或化疗,并完成EORTC QLQ-LC13和QLQ-C30问卷。奥希替尼组咳嗽、胸痛、呼吸困难至恶化时间更长,总体健康状况/生活质量、食欲丧失和疲乏的改善比例更高。
要点
- 奥希替尼较化疗延长咳嗽、胸痛、呼吸困难至恶化时间。
- 奥希替尼组总体健康状况/生活质量改善比例更高(37% vs 22%)。
- 奥希替尼组食欲丧失和疲乏改善的比值比也更高。
核心结论
- 奥希替尼较化疗延长关键症状至恶化时间,并提高总体健康状况/生活质量改善比例,显示更好的患者结局。
研究设计与样本
- AURA3 III期试验,晚期非小细胞肺癌患者接受奥希替尼或化疗,完成EORTC QLQ-LC13和QLQ-C30问卷。
主要发现
- 至恶化时间奥希替尼优于化疗:咳嗽HR 0.74(95%CI 0.53-1.05),胸痛HR 0.52(95%CI 0.37-0.73),呼吸困难HR 0.42(95%CI 0.31-0.58)。
- 食欲丧失改善OR 2.50(95%CI 1.31-4.84),疲乏改善OR 1.96(95%CI 1.20-3.22)。
关键数值与推荐
- 恶化或改善定义为较基线评分变化≥10分。
- HR采用按种族分层的log-rank检验计算;OR采用调整种族的logistic回归评估。
临床怎么用
- 对于晚期非小细胞肺癌,奥希替尼不仅控制肿瘤,还延缓关键症状恶化并改善生活质量。
- 临床决策时可参考患者报告结局,优先考虑能改善症状和生活质量的靶向治疗。
局限性
- 基线问卷完成率为82%-88%,30%-70%患者有 individual 关键症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Capturing patient-reported outcome data is important for evaluating the overall clinical benefits of new cancer therapeutics. We assessed self-reported symptoms of advanced non-small-cell lung cancer in patients treated with osimertinib or chemotherapy in the AURA3 phase III trial. Patients and Methods Patients completed the European Organisation for Research and Treatment of Cancer 13-item Quality of Life Questionnaire-Lung Cancer Module (EORTC QLQ-LC13) questionnaire on disease-specific symptoms and the EORTC 30-item Core Quality of Life Questionnaire (EORTC QLC-C30) on general cancer symptoms, functioning, global health status/quality of life. We assessed differences between treatments in time to deterioration of individual symptoms and odds of improvement (a deterioration or improvement was defined as a change in score from baseline of ≥ 10). Hazard ratios (HRs) were calculated using a log-rank test stratified by ethnicity; odds ratios (ORs) were assessed using logistic regression adjusted for ethnicity. Results At baseline, the questionnaires were completed by 82% to 88% of patients, and 30% to 70% had individual key symptoms. Time to deterioration was longer with osimertinib than with chemotherapy for cough (HR, 0.74; 95% CI, 0.53 to 1.05), chest pain (HR, 0.52; 95% CI, 0.37 to 0.73), and dyspnea (HR, 0.42; 95% CI, 0.31 to 0.58). The proportion of symptomatic patients with improvement in global health status/quality of life was higher with osimertinib (80 [37%] of 215) than with chemotherapy (23 [22%] of 105; OR, 2.11; 95% CI, 1.24 to 3.67; P = .007). Proportions were also higher for appetite loss (OR, 2.50; 95% CI, 1.31 to 4.84) and fatigue (OR, 1.96; 95% CI, 1.20 to 3.22). Conclusion Time to deterioration of key symptoms was longer with osimertinib than with chemotherapy, and a higher proportion of patients had improvement in global health status/quality of life, demonstrating improved patient outcomes with osimertinib.
引用
- Lee CK, Novello S, Rydén A, et al. Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. J Clin Oncol. 2018. PMID: 29733770. doi:10.1200/JCO.2017.77.2293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。